Pharmaceutical Executive, May 1, 2008 - Pharmaceutical Executive

ADVERTISEMENT
Pharmaceutical Executive, May 1, 2008
Features
Special Report: Platform Drugs—Marketing Your Opportunities
By Patrick Angelastro
Tracking business by indication is critical for evaluating market performance and making accurate resource allocations
How Not to Handle Rebates
By John Still , David Carlson
In these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates
Special Report: Platform Drugs—Opportunities in the Market...
By Douglas Martin
How to stretch that portfolio to make ends meet
California Dreaming
By Marylyn Donahue
San Diego's booming biotech cluster searches for its future—and yours
Q&A with Barbara Yanni
How do you find and license the best drugs out there? If you're Merck, you send scientists to go get 'em
Under Pressure
By Susan Vargas
Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work
Beyond the Norm
By Pablo Przygoda
One company's program provides an interesting model for the future of DTP
Korea's Dream Market
By Junghwa Lee
Meet the Korean pharma consumer: affluent, aging, and crazy about drugs
Columns
For the People, By the People
By Lynn O'Connor Vos
Thanks to Dr. Google and Nurse Yahoo, pharma consumers know better than ever how to get exactly what they want
The Incredible Shrinking Dollar
By Walter Armstrong
A plunging currency and other economic turmoil shouldn't phase pharma, right? Yes and no
Staying in the Game
By Sander Flaum
The tech-savvy creative team at Concentric Rx has its sales force mixing work and play
Ready, Aim, Sell
By Anthony Bianciella
Technology isn't the magic bullet, but it can help you hit your target
CME Near and Far: Q&A with Frank F. Britt
A call to embrace cultural differences and translate knowledge into action
Washington Report
FDA to Congress: "Show Us The Money"
By Jill Wechsler
FDA is being pressured to get its act together. The agency says it needs more money and more people to get approvals out the door
Commentary
Boundaries of Expanded Access
By Simon Estcourt, IDIS
More patients are demanding drugs--and showing up everywhere form YouTube to the Supreme Court. But to offer access to investigational drugs, companies first need to know the rules
Opinion
Bringing in the Green
By Porcher L. Taylor III, University of Richmond , David E. Kitchen, University of Richmond
Pharma can stand to win hearts, minds, and tax credits by launching an eco bandwagon
Toolkit
Want to Be in a Health Plan? Think Like One
By Jill Van Bos, Milliman
Pharmacoactuarial analysis helps drug companies communicate value to health plans
Technology
Are You Exposed? Lock Data Down Now
By Mike Fernandes, CYA Technologies
Your current backup and recovery strategy may be leaving you vulnerable to non-compliance, significant revenue loss, and negative brand exposure. Learn how to protect your business
Special Reports
Pharm Exec 50: The Winners Circle
Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.

ADVERTISEMENT

Click here